News and Events

Cole Silver at the NIH Clinical Center for a check-up with Dr. Charalampos Floudas.

Immunotherapy options for head and neck cancers abound at CCR

In the spring of 2017, Cole Silver was diagnosed with head and neck cancer. Over the last few years, he has participated in four clinical trials led by Charalampos Floudas, M.D., D.M.Sc., M.S., Assistant Research Physician, and Julius Strauss, M.D., Associate Research Physician, in the Center for Immuno-Oncology. The variety of trials at NIH gives him hope that he may find a treatment that works for him.

Five years later, an immunotherapy trial for prostate cancer sustains hope

In 2018, we interviewed Tom, a retired surgeon battling prostate cancer who, in 2016, enrolled on an immunotherapy clinical trial led by James Gulley, M.D., Ph.D., Co-Director of the Center for Immuno-Oncology. Now, five years since he first started on the trial, his PSA levels have remained undetectable and his scans continue to come back clean.

Steven A. Rosenberg selected as Icon in Surgery by ACS

Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, has been selected as an Icon in Surgery by the American College of Surgeons. He is being highlighted for being a pioneer in the development of oncologic immunotherapy and gene therapy for patients with advanced cancer. Dr. Rosenberg will be giving a video-based presentation at the 2022 ACS Clinical Congress to discuss his work.

NCI RNA Biology Initiative Retreat - October 25, 2022

RNA biology has emerged as one of the most influential areas in modern biology and biomedicine. NCI is home to a wide spectrum of work in RNA biology ranging from elucidating RNA biogenesis and structure, identifying functions for various classes of RNAs, establishing the role of RNA in disease, and exploring RNA-based and RNA-targeted therapies.

The goal of this retreat, hosted by the NCI RNA Biology Initiative, is to enhance interactions amongst PIs, fellows and staff working on RNA and to foster new collaborations and synergies amongst NIH laboratories interested in RNA biology. The retreat will feature our keynote speaker, Julie M. Claycomb, Ph.D., University of Toronto and several talks selected from submitted abstracts. Fellows, staff scientists and trainees (including Leidos contractors) are encouraged to submit an abstract for consideration. We also hope to catalyze interactions between basic and clinician researchers at this retreat.

Event banner for The Biology & Biophysics of the Nucleus Symposium

Biology & Biophysics of the Nucleus Symposium - October 20-21, 2022

The mission of the Center of Excellence in Chromosome Biology (CECB) is to achieve a comprehensive understanding of the mechanisms involved in chromosome function, how aberrations in chromosomes and chromatin lead to disease and how these defects can be corrected.

Towards achieving the mission, the Biology & Biophysics of the Nucleus Symposium brings together scientists in the fields of chromatin and chromosome biology, with the focus on stem cells, cell development, aging and cancer.

We hope this symposium offers you an opportunity to learn more about the current status of chromosome structure and function in development and disease, to share your research and to discuss the use and implications of these advances for clinical applications.

Organized by: Shalini Oberdoerffer, Ph.D., Gordon Hager, Ph.D., and Dave Levens, M.D., Ph.D.

Clinical trial researching therapy for bile duct cancer

A clinical trial led by Jonathan Hernandez, M.D., Investigator in the Surgical Oncology Program, is researching a combination of immunotherapy and chemotherapy for liver-only cholangiocarcinoma.

The middle portion of the gastrointestinal tract is a common location for cancerous neuroendocrine tumors to form.

Clinical trial evaluates drug combination for inoperable neuroendocrine tumors

Neuroendocrine tumors occur in cells of the endocrine and nervous systems. A combined phase I/II clinical trial at the NIH Clinical Center evaluates the effectiveness of a combination of two agents that may work in complementary ways to target inoperable or metastatic neuroendocrine tumors.

image of female physician using a stethoscope on a young female patient

Clinical trial researching T-cell therapy for sarcoma

John W. Glod, M.D., Ph.D., Associate Research Physician in the Pediatric Oncology Branch, is leading NCI’s participation in a clinical trial researching T-cell therapy for sarcomas.

Three-dimensional illustration of a T cell attacking a cancer cell.

T-cell imbalance can impact immunotherapy outcomes

The rapid growth of a patient’s cancer following immune checkpoint inhibitor therapy, known as hyperprogressive disease, is an unexpected treatment outcome that is challenging to predict or study. New results show that a T-cell imbalance in the tumor microenvironment can trigger the condition.

A spheroid of breast cancer cells grown in a three-dimensional matrix.

Mapping cells’ mechanical properties for insight into metastasis

A new approach allows researchers to investigate cells’ mechanical properties in tissue-like environments.

Breadcrumb